CirrhosisNCT04940416
Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease
An observational study of Cirrhosis and Hepatic Encephalopathy, run by Stanford University at 1 site in United States.
Trial summary
This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Cirrhosis, Hepatic Encephalopathy
- What is being tested?
- Neurofit (oculometric testing)
- Type of treatment
- Medical device
- How many people
- 48 participants
- Where
- 1 siteUnited States
- Study dates
- 31 Aug 2017to 17 Jun 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will include consenting patients with cirrhosis seen in the gastroenterology and hematology clinic of the Stanford hospital. They will include patients with cirrhosis of varying severity. The non cirrhosis arm will include patients in the general gastroenterology clinic with no laboratory or radiological evidence of cirrhosis.
Who may be able to join
- Patients with cirrhosis with clinical appointments in the pretransplant liver clinic
- Patients in the general gastroenterology clinic without a diagnosis of cirrhosis (controls)
Who cannot join
- Individuals <18 years
- cirrhotic patients with hepatocellular cancer
- individuals with uncontrolled neuropsychiatric illnesses or overt hepatic encephalopathy
- ongoing alcohol or illicit substance use
- non-English speakers, as the language barrier may impact psychometric test results
Trial locations and contacts
1 site in 1 country.
United States1 site
Stanford University School of Medicine
Redwood City, California, 94063
About this study
Official title: Oculometric Testing for the Diagnosis of Covert Hepatic Encephalopathy
This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics.
Read the detailed description
Cirrhosis is an increasingly prevalent medical condition in the United States that impacts health-related quality of life, healthcare resource utilization and survival. Patients with decompensated cirrhosis occasionally suffer from hepatic encephalopathy which is a serious complication that results from portosystemic shunting of blood leading to a spectrum of neuropsychiatric changes and alteration in consciousness levels when it becomes overt (overt hepatic encephalopathy, OHE).
Hepatic encephalopathy affects 30-45% of patients with cirrhosis and its occurrence and progression is associated with higher mortality.
In particular, Hepatic encephalopathy (HE) is an independent predictor of hospital readmissions in patients with cirrhosis. Encephalopathy could be overt with obvious deterioration in the level of consciousness leading to hospitalizations, but could also be covert and less obvious to the patient and healthcare provider.
Covert hepatic encephalopathy (CHE) is often unrecognized by healthcare providers leading to falls, motor vehicular accidents, and potential progression to overt confusion. Progression of CHE to OHE makes recognition of this condition important as early identification and treatment can potentially improve quality of life, reduce hospital readmissions and healthcare costs. Existing diagnostic tools are not only tedious and time consuming, but also impacted by factors such as level of education, reducing their utility in clinical practice. The ideal test would be easy to use, quantifiable, quick, cheap, reliable, and able to predict outcomes.
The exploratory study will utilize a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing. Eye movements are short latency, voluntary motor behaviors that consist of various aspects including visual motion, pursuit initiation, steady-state tracking, direction tuning, and speed tuning. The computer application is based on an eye movement methodology that can quantify many aspects of human dynamic visual processing using a noninvasive video-based eye tracking technology with validated oculometric analysis techniques.
Prior studies have demonstrated sensorimotor dysfunction in patients with diffuse brain injury which leads to derangement in information processing throughout the brain. This computer application has been utilized in patients with traumatic brain injury (TBI). Liston et al, in a study of 34 TBI patients, demonstrated that TBI patients had several individual oculometrics that were significantly deranged including pursuit latency, initial pursuit acceleration, pursuit gain, catch-up saccade amplitude, proportion smooth tracking, and speed responsiveness as compared to a separate control group. The application was able to discriminate TBI subjects from controls with an 81% probability that increased with self-reported TBI severity.
Rationale Hepatic encephalopathy is believed to occur as a consequence of portosystemic shunting leading to toxins, octapamines, free fatty acids amongst others accumulating in the brain, causing impairment in neurocognitive functioning. The extent of brain dysfunction associated with hepatic encephalopathy has not been fully characterized. Hepatic encephalopathy could potentially impair global brain function leading to oculomotor discoordination that can be detected with this computer software. By comparing individual and composite oculometric data between patients with cirrhosis and those without cirrhosis this study may identify any significant differences or distinct patterns that may exist as a result of hepatic encephalopathy. For this study, covert hepatic encephalopathy will be determined by paper-based psychometric testing. Any data obtained from this feasibility/exploratory study, will serve as preliminary data for larger studies and future validation.
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Being tested
- Neurofit (oculometric testing)
- Medical subject headings
- Fibrosis, Hepatic Encephalopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neurofit (oculometric testing)Device
The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Cirrhosis | These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes. Receives: Device: Neurofit (oculometric testing) | |
| Non-cirrhosis | These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes. Receives: Device: Neurofit (oculometric testing) |
What is being measured
The primary outcome is the main question the study is designed to answer.
NeuroFit score
Composite oculometric test result
Measured: at first visit (up to 5 minutes)
Secondary outcomes (1)
Psychometric hepatic encephalopathy score
Composite score from paper based psychometric test
Measured: at first visit (up to 10 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2021
- Study start31 Aug 2017
- Primary completion17 Jun 2021
- Study completion17 Jun 2021
Why it stopped: Collaboration between partners ended, covid
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CirrhosisStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- Neurofit Inc, Mountain View, California
- Responsible party
- Principal investigator, POkafor, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04940416
- Sponsor's protocol ID
- 41796
- Status last verified
- Jun 2021
- First submitted
- 17 Jun 2021
- Last updated
- 25 Jun 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Oculometric Testing for the Diagnosis of Covert Hepatic Encephalopathy
- ClinicalTrials.gov ID
- NCT04940416
- Acronym / sponsor ID
- 41796
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Collaboration between partners ended, covid
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- Neurofit Inc, Mountain View, California
- Study start
- 31 Aug 2017 (actual)
- Primary completion
- 17 Jun 2021 (actual)
- Study completion
- 17 Jun 2021 (actual)
- First posted
- 25 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study involves utilizing a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing in patients with liver cirrhosis to see if the presence of advance liver disease influences eye movement metrics.
Detailed description
Cirrhosis is an increasingly prevalent medical condition in the United States that impacts health-related quality of life, healthcare resource utilization and survival. Patients with decompensated cirrhosis occasionally suffer from hepatic encephalopathy which is a serious complication that results from portosystemic shunting of blood leading to a spectrum of neuropsychiatric changes and alteration in consciousness levels when it becomes overt (overt hepatic encephalopathy, OHE).
Hepatic encephalopathy affects 30-45% of patients with cirrhosis and its occurrence and progression is associated with higher mortality.
In particular, Hepatic encephalopathy (HE) is an independent predictor of hospital readmissions in patients with cirrhosis. Encephalopathy could be overt with obvious deterioration in the level of consciousness leading to hospitalizations, but could also be covert and less obvious to the patient and healthcare provider.
Covert hepatic encephalopathy (CHE) is often unrecognized by healthcare providers leading to falls, motor vehicular accidents, and potential progression to overt confusion. Progression of CHE to OHE makes recognition of this condition important as early identification and treatment can potentially improve quality of life, reduce hospital readmissions and healthcare costs. Existing diagnostic tools are not only tedious and time consuming, but also impacted by factors such as level of education, reducing their utility in clinical practice. The ideal test would be easy to use, quantifiable, quick, cheap, reliable, and able to predict outcomes.
The exploratory study will utilize a noninvasive computer application (Neurofit) that performs oculometric assessment of dynamic visual processing. Eye movements are short latency, voluntary motor behaviors that consist of various aspects including visual motion, pursuit initiation, steady-state tracking, direction tuning, and speed tuning. The computer application is based on an eye movement methodology that can quantify many aspects of human dynamic visual processing using a noninvasive video-based eye tracking technology with validated oculometric analysis techniques.
Prior studies have demonstrated sensorimotor dysfunction in patients with diffuse brain injury which leads to derangement in information processing throughout the brain. This computer application has been utilized in patients with traumatic brain injury (TBI). Liston et al, in a study of 34 TBI patients, demonstrated that TBI patients had several individual oculometrics that were significantly deranged including pursuit latency, initial pursuit acceleration, pursuit gain, catch-up saccade amplitude, proportion smooth tracking, and speed responsiveness as compared to a separate control group. The application was able to discriminate TBI subjects from controls with an 81% probability that increased with self-reported TBI severity.
Rationale Hepatic encephalopathy is believed to occur as a consequence of portosystemic shunting leading to toxins, octapamines, free fatty acids amongst others accumulating in the brain, causing impairment in neurocognitive functioning. The extent of brain dysfunction associated with hepatic encephalopathy has not been fully characterized. Hepatic encephalopathy could potentially impair global brain function leading to oculomotor discoordination that can be detected with this computer software. By comparing individual and composite oculometric data between patients with cirrhosis and those without cirrhosis this study may identify any significant differences or distinct patterns that may exist as a result of hepatic encephalopathy. For this study, covert hepatic encephalopathy will be determined by paper-based psychometric testing. Any data obtained from this feasibility/exploratory study, will serve as preliminary data for larger studies and future validation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cirrhosis | – | Device: Neurofit (oculometric testing)These will include patients with cirrhosis. They will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes. |
| Non-cirrhosis | – | Device: Neurofit (oculometric testing)These will include patients without cirrhosis seen in the general gastroenterology clinic. Participants will perform the paper-based standard psychometric tests (number connection test A, number connection test B, line tracing test, and digital subtraction test, and serial dotting test, which take about 20 minutes). After completion of paper-based standard psychometric tests, participants will then perform the computer application test which takes about 5 minutes. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include consenting patients with cirrhosis seen in the gastroenterology and hematology clinic of the Stanford hospital. They will include patients with cirrhosis of varying severity. The non cirrhosis arm will include patients in the general gastroenterology clinic with no laboratory or radiological evidence of cirrhosis.
Key inclusion criteria (2 listed)
- Patients with cirrhosis with clinical appointments in the pretransplant liver clinic
- Patients in the general gastroenterology clinic without a diagnosis of cirrhosis (controls)
Key exclusion criteria (5 listed)
- Individuals <18 years
- cirrhotic patients with hepatocellular cancer
- individuals with uncontrolled neuropsychiatric illnesses or overt hepatic encephalopathy
- ongoing alcohol or illicit substance use
- non-English speakers, as the language barrier may impact psychometric test results
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neurofit (oculometric testing)The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes. | Device | Cirrhosis, Non-cirrhosis |
Primary outcome
NeuroFit score
Time frame: at first visit (up to 5 minutes)
Composite oculometric test result
1 secondary outcome
Psychometric hepatic encephalopathy score
Time frame: at first visit (up to 10 minutes)
Results and safety
The study was stopped early (reason given: Collaboration between partners ended, covid). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2021.
- Individual participant dataSharing planned: No
Related trials for Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cirrhosis and Hepatic Encephalopathy, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 25 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Collaboration between partners ended, covid). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NeuroFit score (time frame: at first visit (up to 5 minutes)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2021.